PMID- 26547338
OWN - NLM
STAT- MEDLINE
DCOM- 20160125
LR  - 20181202
IS  - 1673-4254 (Print)
IS  - 1673-4254 (Linking)
VI  - 35
IP  - 10
DP  - 2015 Oct
TI  - [Manual immunohistochemistry for detecting ALK gene fusion antibody in 519 cases 
      of non-small lung cancer].
PG  - 1440-5
AB  - OBJECTIVE: To investigate the expression of anaplastic lymphoma kinase (ALK) gene 
      fusion antibody in non-small cell lung cancer (NSCLC) and explore the 
      clinicopathological significance. METHODS: Using manual immunohistochemistry 
      (IHC) with D5F3 rabbit monoclonal antibody, we detected the expression of ALK 
      gene fusion protein in 519 cases of NSCLC. The relations of ALK fusion protein 
      with the clinical characteristics of the patients and the histological 
      classification of the tumors were analyzed. The expressions of ALK fusion protein 
      were compared between surgical specimens and biopsy samples, and the consistency 
      of manual IHC results was evaluated with the results of a fully automated IHC 
      instrument and fluorescence in situ hybridization (FISH). RESULTS: The positivity 
      rate of ALK fusion protein was 11.37% (59/519) among the cases detected by manual 
      IHC. The patients tended to have a young age of onset (P=0.048) and most of the 
      tumors were adenocarcinoma. In the surgical specimens, ALK fusion protein was 
      expressed mostly in invasive mucinous adenocarcinoma (P<0.01), and it was a high 
      risk factor of lymph node metastasis [OR=2.188(95%C.I:1.161-4.122)]. No 
      statistical difference was found in the test results of manual IHC between 
      surgical specimens and biopsy samples. The results by manual IHC suggesting a 
      strong expression were consistent with the results by automated IHC and FISH. 
      CONCLUSION: Manual IHC can be reliable for screening ALK fusion arrangement in 
      patients with NSCLC.
FAU - Gu, Xia
AU  - Gu X
AD  - Department of Pathology, First Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou 510120, China. E-mail: guxia1373@163.com.
FAU - Wu, Jie-Yu
AU  - Wu JY
FAU - He, Xin-Ming
AU  - He XM
FAU - He, Ping
AU  - He P
FAU - Fu, Xin-Ge
AU  - Fu XG
FAU - Lin, Yun-En
AU  - Lin YE
FAU - Li, Guang-Qiu
AU  - Li GQ
FAU - Hao, Yan
AU  - Hao Y
LA  - chi
PT  - Journal Article
PL  - China
TA  - Nan Fang Yi Ke Da Xue Xue Bao
JT  - Nan fang yi ke da xue xue bao = Journal of Southern Medical University
JID - 101266132
RN  - 0 (Antibodies)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adenocarcinoma/genetics
MH  - Anaplastic Lymphoma Kinase
MH  - Antibodies
MH  - Carcinoma, Non-Small-Cell Lung/*genetics
MH  - *Gene Fusion
MH  - Humans
MH  - *Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*genetics
MH  - Receptor Protein-Tyrosine Kinases/genetics/*immunology
EDAT- 2015/11/10 06:00
MHDA- 2016/01/26 06:00
CRDT- 2015/11/09 06:00
PHST- 2015/11/09 06:00 [entrez]
PHST- 2015/11/10 06:00 [pubmed]
PHST- 2016/01/26 06:00 [medline]
PST - ppublish
SO  - Nan Fang Yi Ke Da Xue Xue Bao. 2015 Oct;35(10):1440-5.